作者
Jennifer L Caswell-Jin, Sylvia K Plevritis, Lu Tian, Christopher J Cadham, Cong Xu, Natasha K Stout, George W Sledge, Jeanne S Mandelblatt, Allison W Kurian
发表日期
2018/10
来源
JNCI cancer spectrum
卷号
2
期号
4
页码范围
pky062
出版商
Oxford University Press
简介
Background
Metastatic breast cancer (MBC) treatment has changed substantially over time, but we do not know whether survival post-metastasis has improved at the population level.
Methods
We searched for studies of MBC patients that reported survival after metastasis in at least two time periods between 1970 and the present. We used meta-regression models to test for survival improvement over time in four disease groups: recurrent, recurrent estrogen (ER)-positive, recurrent ER-negative, and de novo stage IV. We performed sensitivity analyses based on bias in some studies that could lead earlier cohorts to include more aggressive cancers.
Results
There were 15 studies of recurrent MBC (N = 18 678 patients; 3073 ER-positive and 1239 ER-negative); meta-regression showed no survival improvement among patients recurring between 1980 and …
学术搜索中的文章
JL Caswell-Jin, SK Plevritis, L Tian, CJ Cadham, C Xu… - JNCI cancer spectrum, 2018